Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1%
| Status: | Archived |
|---|---|
| Conditions: | Ocular |
| Therapuetic Areas: | Ophthalmology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | November 2010 |
| End Date: | May 2011 |
Clinical Outcomes of Bromday (Bromfenac Ophthalmic Solution) 0.09% QD vs. Nevanac (Nepafenac Ophthalmic Suspension) 0.1% TID for Treatment of Ocular Inflammation Associated With Cataract Surgery
This is a single-center, randomized, investigator-masked, parallel group, and
active-comparator controlled study investigating the clinical outcomes for visual acuity and
macular thickness after treatment with Bromday (bromfenac ophthalmic solution) 0.09% QD or
Nevanac (nepafenac ophthalmic suspension) 0.1% TID in subjects who have undergone cataract
extraction with posterior chamber intraocular lens implantation.
We found this trial at
1
site
Click here to add this to my saved trials
